Sujets)
Humains , Nouveau-né , Néonatologie , Nouveau-né/immunologie , Nouveau-né/métabolisme , Nouveau-né/sang , Transfusion sanguine/méthodes , Transfusion sanguine/normes , Anémie néonatale , Agents hématologiques/pharmacologie , Volume sanguin , Érythropoïèse , Oxygénation extracorporelle sur oxygénateur à membrane , Test d'histocompatibilité , Transfusion de composants du sang/méthodesRésumé
Alternative therapeutic interventions in Type II lepra reaction are being considered following serious problems associated with the use of steroids and thalidomide. Pentoxifylline (PTX) has been used in Type II reaction with varying degrees of success. The results of a study on the use of this drug in a dose of 1200 mg per day for a period of 2 months in patients with ENL reaction are discussed. Five patients, one of whom was HIV positive--all with severe Type II reaction, were regularly evaluated for regression of inflammatory symptoms and clinical involution of ENL lesions while on PTX therapy and thereafter. It was found that PTX led to a total elimination of systemic symptoms within a week. ENL lesions regressed in two weeks. However, in one patient, lesions recurred after one month of therapy. It appears that PTX is well tolerated and could be used as an additional drug in the armamentarium of leprologists in the management of Type II reaction, especially in HIV co-infection, where long-term steroids are contraindicated. However, further studies to compare the effects of PTX with currently, widely used drugs for the treatment of ENL reaction are necessary.